Atherosclerosis, inflammation, and infection

Journal of Pathology

Volumn 190, Issue 3, 2000, Pages 237-243

  De Boer, Onno J ^a   Van Der Wal, Allard C ^a   Becker, Anton E ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chlamydia pneumoniae; CMV; Helicobacter pylori; Plaque complications

Indexed keywords

ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE ACTIVATION; MAST CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ACUTE-PHASE PROTEINS; ANTIBODY FORMATION; ARTERIOSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION;

EID: 0034094340     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:3<237::AID-PATH541>3.0.CO;2-N     Document Type: Review

References (64)

1. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-175.
2. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 1988; 72: 135-141.
3. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-170.
4. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-1678.
5. van der Wal AC, Becker AE. Atherosclerotic plaque rupture pathologic basis of plaque stability and instability. Cardiovasc Res 1999; 41: 334-344.
6. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992; 12: 206-211.
7. van der Wal AC, Piek JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 1998; 80: 14-18.
8. Whicher J, Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999; 37: 495-503.
9. van der Wal AC, Dingemans K, van den Bergh Weerman MA, Das PK, Becker AE. Specialized membrane contacts between immunocompetent cells in human atherosclerotic plaques. Cardiovasc Pathol 1994; 3: 81-85.
10. de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, Becker AE. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 1997; 133: 227-234.
11. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-283.
12. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138.
13. Frostegård J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
14. de Boer OJ, van der Wal AC, Verhagen CE, Becker AE. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol 1999; 188: 174-179.
15. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92: 1084-1088.
16. Kaartinen M, van der Wal AC, van der Loos CM, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. JACC 1998; 32: 606-612.
17. High KP. Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence. Clin Infect Dis 1999; 28: 746-749.
18. Tiran A, Tio RA, Oostenveld E, et al. Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty. Clin Diagn Lab Immunol 1999; 6: 45-49.
19. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120: 93-99.
20. Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177: 209-212.
21. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2: 644-647.
22. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-2148.
23. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-28.
24. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42: 170-174.
25. Blum A, Giladi M, Weinberg M, et al. High anticytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81: 866-868.
26. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989; 261: 3561-3566.
27. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection [see comments]. Am J Cardiol 1989; 64: 359-362.
28. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996; 74: 921-931.
29. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-439.
30. Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998; 98: 845-850.
31. Malnick SDH, Goland S, Kaftoury A, et al. Evaluation of carotid arterial plaques after endarterectomy for Helicobacter pylori infection. Am J Cardiol 1999; 83: 1586-1587.
32. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-1679.
33. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
34. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-238.
35. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176: 292-295.
36. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. JACC 1998; 31: 827-832.
37. Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999; 99: 2733-2736.
38. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 1995; 92: 6911-6914.
39. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150: 1785-1790.
40. Halme S, Syrjala H, Bloigu A, et al. Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997; 18: 1095-1101.
41. Halme S, Juvonen T, Laurila A, et al. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 1999; 29: 546-552.
42. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol 1979; 96: 673-706.
43. Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gonczol E. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998; 5: 39-47.
44. Tanaka K, Zou JP, Takeda K, et al. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation 1999; 99: 1656-1659.
45. Zhou YF, Guetta E, Yu ZX, Finkel T, Epstein SE. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest 1996; 98: 2129-2138.
46. Zhou YF, Yu ZX, Wanishsawad C, Shou M, Epstein SE. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun 1999; 256: 608-613.
47. Hu H, Pierce GN, Zhong GM. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-753.
48. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumonias infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Inject Dis 1999; 180: 238-241.
49. Laitinen K, Laurila A, Pyhala L. Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65: 4832-4835.
50. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
51. van Deventer SJ. Chlamydia pneumoniae as a causative agent in atherosclerosis. Ned Tijdschr Geneesk 1999; 143: 288-290 (in Dutch).
52. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Injection 1999; 1: 409-118.
53. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-1373.
54. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99: 1560-1566.
55. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33.
56. Xu Q, Kleindienst R, Waitz W, Dietrich H, Wick G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest 1993; 91: 2693-2702.
57. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-259.
58. Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-799.
59. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-577.
60. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-307.
61. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharm 1995; 25: S9-S12.
62. Mach F, Schonbeck U, Libby P. CD40 signalling in vascular cells - a key role in atherosclerosis. Atherosclerosis 1998; 137: S89-S95.
63. Gupta S, Leatham EW, Carrington D. Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
64. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection the azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-1547.